Shandong Buchang Pharmaceuticals Co., Ltd. (SHA:603858)

SHA:603858 Revenue

Shandong Buchang Pharmaceuticals had revenue of 3.01B CNY in the quarter ending September 30, 2026, with 7.47% growth. This brings the company's total for the last twelve months to 11.42B, up 4.23% year-over-year. In the year 2025, Shandong Buchang Pharmaceuticals had annual revenue of 11.88B with 7.90% growth. That makes Shandong Buchang Pharmaceuticals the 5,540th largest company in the world by revenue and 727th in China.

• Revenue (ttm): 11.42B
• Revenue Growth: +4.23%
• P/S Ratio: 1.37
• Revenue / Employee: 1.58M
• Employees: 7,237
• Market Cap: 15.67B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Pharmaceutical Divison 10.66B 82.4%
• Pharmaceutical Sales 1.48B 11.5%
• Other Operations 790.94M 6.1%

By Geography

Chart

• East China Region 2.87B 24.2%
• Central China Region 2.63B 22.2%
• North China Region 2.29B 19.4%
• Northeast Region 1.41B 11.9%
• Northwest Region 1.39B 11.7%
• Southwest Region 1.23B 10.4%
• Export 29.52M 0.2%

Fiscal year ended Dec 31, 2025 See the full SHA:603858 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	11.88B	869.22M	7.90%
Dec 31, 2024	11.01B	-2.24B	-16.91%
Dec 31, 2023	13.25B	-1.71B	-11.41%
Dec 31, 2022	14.95B	-811.43M	-5.15%
Dec 31, 2021	15.76B	-244.03M	-1.52%

Data Source: S&P Global Market Intelligence Last updated: Oct 29, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 5, 2026

Data Sources Report a data error